InvestorWire NewsRoom


Articles Category: Psychedelics
Thursday May 19, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Adds Neuro-enhancing Therapies to 6 KWC Clinics, With Plans to Expand Across the Nation

Delic Holdings Corp works to develop novel solutions for hard-to-treat mental and emotional disordersThe company’s Ketamine Wellness Centers (“KWC”) clinical subsidiary recently announced the addition of NAD+ (nicotinamide adenine dinucleotide) infusion therapies as a means of boosting natural energy stores and immunity, brain and DNA function, and cell communicationThe NAD+ therapies will launch in six of KWC’s clinics on May 9 — in Jacksonville, Fla.;…

Continue Reading

Tuesday May 17, 2022 - 9:45 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Capitalizing on Psychedelics Drug Market, with 13 Wellness Clinics Across Nine States and Growing

Delic Holdings Corp. comprises several businesses—Delic Labs, Meet Delic, and Ketamine Wellness Centers and media properties Reality Sandwich and Delic Radio The psychedelic drugs market is expected to reach US $9,818.68 million by 2029 – primarily driven by an increase in acceptance for use in mental healthThe company’s goal is to expand its clinic offering to 60-70% of the American population driving no more than 45-minutes…

Continue Reading

Wednesday May 11, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or…

Continue Reading

Friday May 06, 2022 - 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”)MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwidePreclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO:…

Continue Reading

Tuesday May 03, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Set to Present Update on its Psychedelic Wellness Ecosystem at Las Vegas MicroCap Event

Delic Holdings Corp was founded four years ago, devoted to making psychedelic drug therapies available to patients with hard-to-treat mental and emotional conditions The company’s research arm has received authorization in Canada to work with substances such as psilocybin, MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-BIn the United States, the company operates the country’s largest chain of ketamine (anesthesia-related medication) clinics for wellness therapiesDelic Co-founder…

Continue Reading

Friday Apr 29, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Driving the Psychedelic Conversation Forward Through Education, Research, and Service Delivery

Delic is committed to bringing science-backed benefits to as many people as possible while also changing the narrative around psychedelicsIt seeks to achieve this through education, products and services, and research on psychedelics So far, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patientsDelic recognizes the potential of psychedelics and their application in therapeutics, hence its investment in research,…

Continue Reading

Thursday Apr 28, 2022 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeuticCybin is currently developing CYB004 for the treatment of anxiety disordersThe new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”)…

Continue Reading

Wednesday Apr 27, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Moves to Become the Go-To Provider of Psychedelic Medicine Treatment as it Seeks Approval of Additional Compounds

Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment optionsThe company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 diseaseDelic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United StatesWith 13 clinics already in operation, Delic is eyeing expansion…

Continue Reading

Wednesday Apr 20, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Achieves Key Milestone in the Advancement of Its Research Efforts

Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic researchThe company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposesWith this significant milestone, Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness…

Continue Reading

Monday Apr 18, 2022 - 9:30 am

Mullen Automotive Inc. (NASDAQ: MULN) Named EV Startup to ‘Watch Out For’ by Leading Auto Site

Mullen called “dark horse” in HotCars 2022 list of top EV startupsOther online articles also shining spotlight on what CarBuzz calls “the real deal” Mullen CEO calls FIVE model “just the start” Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is starting the new year with a bang: the company is ranked no. 2 on the HotCars 2022 list of top-10 EV startups (…

Continue Reading

Monday Apr 18, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent applicationPublication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment optionsCompany continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods…

Continue Reading

Wednesday Apr 13, 2022 - 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable

Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressantIts introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through…

Continue Reading

Tuesday Apr 12, 2022 - 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disordersIt also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolioFor 2022, the company plans to build on the progress achieved in 2021With new additions to its board, its conditional IRB approval, and the…

Continue Reading

Monday Apr 11, 2022 - 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine”Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeuticallySILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as…

Continue Reading

Friday Apr 08, 2022 - 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and moreCybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated…

Continue Reading

Tuesday Apr 05, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging.Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being.Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study…

Continue Reading

Tuesday Apr 05, 2022 - 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel moleculesThe world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemicMydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT…

Continue Reading

Monday Apr 04, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO to Present at Three Upcoming Investor Conferences Spotlighting the Company’s Strategic Outlook for the Remainder of 2022

Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences ConferenceIn presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the yearDuring a recent interview on The Jesse Tee Show, Stang noted the company intends…

Continue Reading

Monday Mar 28, 2022 - 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addictionMydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trialsThe company is targeting nicotine addiction…

Continue Reading

Friday Mar 25, 2022 - 9:00 am

Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Makes Psychedelic Treatment More Accessible with Opening of New Reno Clinic

Following the acquisition of KWC back in November 2021, Delic Holdings Corp set out to open additional state-of-the-art ketamine infusion treatment clinics over the course of 18 monthsThe company has just announced the opening of its second clinic in Nevada in a move that will serve both local patients and those in larger California markets without access to affordable in-state providersDelic is still set to…

Continue Reading

Thursday Mar 24, 2022 - 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year.Psilocybin could lead to significant, durable improvements in depression.Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients ( That bodes…

Continue Reading

Thursday Mar 17, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Aiming to Reach Millions of Mental Health Patients with Effective, Affordable Ketamine Treatments

Mental health conditions affect millions of people globally, some of whom are resistant to existing treatmentsIn the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatmentDelic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes…

Continue Reading

Thursday Mar 17, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic optionsGrowing number of cities, states looking at decriminalizing use of psychedelic medicineCybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a…

Continue Reading

Wednesday Mar 16, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leverages Research to Promote Mental Health

Delic Holdings Corp, a leader in new medicines and treatments for a modern world, understands that research is integral for both the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for the treatment of mental health issuesDr. Markus Roggen, President and CSO of Delic Labs, recently spoke at this year’s Emerald Conference, and has reiterated the importance of leveraging AI…

Continue Reading

Thursday Mar 03, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patentPatent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compoundsCYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office…

Continue Reading

Monday Feb 28, 2022 - 9:45 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Tackles Pandemic-era Mental Health Crises with Product R&D and Educational Efforts for the Application of Psychedelics Technology

Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needsDelic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness clinics providing ketamine treatments in the U.S.; Reality Sandwich and Meet…

Continue Reading

Monday Feb 28, 2022 - 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005

Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compoundsMydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nauseaThe company is excited about this finding, terming it one of the many…

Continue Reading

Friday Feb 25, 2022 - 9:15 am

Nemaura Medical Inc. (NASDAQ: NMRD) Publishes 3QFY2022 Results; Company Reports its Inaugural Quarterly Revenues

Nemaura Medical has recently reported its 3QFY2022 (4QCY2021) results, with the company recognizing its inaugural revenues of $183,628 over the quarterThe company also announced that it held $23 million in cash reserves as of the end of the quarter, which should amply cover its cash requirements over the coming monthsNemaura Medical seized upon the opportunity to update investors on their ongoing operational highlights, which include…

Continue Reading

Wednesday Feb 23, 2022 - 10:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSDThese results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizonMydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academicsIn a recent interview, company…

Continue Reading

Tuesday Feb 22, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare

The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available83% of Americans living with these conditions are open to trying out alternative treatmentsDelic seeks to capitalize on this growing…

Continue Reading

Tuesday Feb 15, 2022 - 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addictionMydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment optionsThe license allows Mydecine to provide psilocybin and MDMA…

Continue Reading

Tuesday Feb 15, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion planIn a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made availableStudies such as these are helping Delic drive the conversation on psychedelics forwardThe company seeks to take this…

Continue Reading

Monday Feb 14, 2022 - 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technologyKernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experienceCYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward…

Continue Reading

Friday Feb 11, 2022 - 9:15 am

Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Delic Labs to Present Latest Results and Insights from Its Extensive Experimental Studies on Cannabis Extraction at the Emerald Conference on February 28

Delic Lab’s President and Chief Science Officer, Dr. Markus Roggen, will present at the upcoming Emerald Conference on February 28Delic Labs is a federally licensed research laboratory operating as part of the Delic Holdings ecosystemThe laboratory focuses on extraction optimization, analytical testing, and chemical product and process development and is likely to continue supporting the cannabis industry with the latest technology and services as the…

Continue Reading

Wednesday Feb 02, 2022 - 12:38 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compoundMydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwideThe LOI is the first collaboration under Mydecine’s SASSP program, which will provide psychedelic drug…

Continue Reading

Monday Jan 31, 2022 - 1:03 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics.Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. Study may provide crucial “mind-imaging” information that has been previously missing. Cybin (NEO: CYBN) (NYSE American: CYBN) is starting off the new year right — the company has received approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative…

Continue Reading

Thursday Jan 27, 2022 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuseWell+Good says psychedelics “poised to change the course of mental health treatment”Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process A USA Today article is touting psychedelics as the next big thing in mental health treatment ( This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE…

Continue Reading

Tuesday Jan 25, 2022 - 12:15 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Reports Findings of Commissioned Study Showing a Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment for Select Mental Conditions

The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSDThe survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were…

Continue Reading

Monday Jan 24, 2022 - 12:28 pm

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices

Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapyThe products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy supportThe planned launch follows an amendment to federal regulations allowing physicians to…

Continue Reading

Friday Jan 21, 2022 - 10:37 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Corporate Update Points to Profitability in 2022 and Beyond

In 2021, Delic’s investments and acquisitions allowed for an annualized revenue run-rate of over $9MMGoing into the new year, the company looks forward to opening additional ketamine infusion treatment clinics, growing them by 15 within the next 18 monthsDelic’s growth has been attributed to the strong demand for alternatives to current treatments for mental health conditionsIts management is confident that the foundations laid down so…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).